{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Relmada Therapeutics, Inc.
Is Relmada Therapeutics, Inc. technically bullish or bearish?
As of June 11, 2025, the market trend is mildly bearish, supported by daily moving averages and Dow Theory, despite some mixed bullish signals from the MACD and KST on longer time frames.
Who are in the management team of Relmada Therapeutics, Inc.?
As of March 2022, the management team of Relmada Therapeutics, Inc. includes Independent Chairman Charles Casamento, CEO Sergio Traversa, and Independent Directors John Glasspool, Paul Kelly, and Eric Schmidt, who collectively guide the company's strategic direction and operations.
What does Relmada Therapeutics, Inc. do?
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for central nervous system disorders, with a market cap of $23.37 million and a recent net profit of -$18 million. The company is classified as a micro-cap and has no dividend yield.
How big is Relmada Therapeutics, Inc.?
As of Jun 18, Relmada Therapeutics, Inc. has a market capitalization of 23.37 million, with net sales of 0.00 million and a net profit of -75.72 million over the latest four quarters. Shareholder's funds are at 35.52 million, and total assets are 45.82 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
